Y. J. Xie et al. demonstrated that CAR-T cells targeting PD-L1 could reduce tumor growth and improve survival outcomes in animal models, suggesting the potential for reprogramming the tumor microenvironment and enhancing CAR-T therapy in solid tumors [87]. The gene discussed is CD274; the disease is neoplasm.